Scientific and regulatory considerations on the immunogenicity of biologics

Trends in Biotechnology

Volumn 24, Issue 6, 2006, Pages 274-280

  Shankar, Gopi ^a   Shores, Elizabeth ^b   Wagner, Carrie ^a   Mire Sluis, Anthony ^c  

^a CENTOCOR INC   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCIDENT PREVENTION; BIOTECHNOLOGY; HEALTH CARE; PATIENT TREATMENT; VACCINES;

ADMINISTRATION REACTIONS; DEFICIENCY SYNDROMES; HYPERSENSITIVITY; IMMUNOGENICITY;

IMMUNOLOGY;

CHIMERIC ANTIBODY; DRUG ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; SYNTHETIC PEPTIDE;

ANTIBODY RESPONSE; ANTIGEN BINDING; CELLULAR IMMUNITY; CLINICAL RESEARCH; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PHARMACOGENETICS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; VALIDATION PROCESS;

ANIMALS; ANTIBODIES; BIOLOGICAL PRODUCTS; DRUG APPROVAL; GUIDELINES; HUMANS; IMMUNOGENETICS;

EID: 33744950980     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2006.04.001     Document Type: Review

References (41)

1. Schellekens H. The immunogenicity of biopharmaceuticals. Neurology 61 (2003) S11-S12
2. Koren E., et al. Immune responses to therapeutic proteins in humans - clinical significance, assessment, and prediction. Curr. Pharm. Biotechnol. 3 (2002) 349-360
3. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24 (2002) 1720-1740
4. Pendley C., et al. Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Ther. 5 (2003) 172-179
5. Gribben J.G., et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335 (1990) 434-437
6. Antonelli G., et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy. Clin. Exp. Immunol. 104 (1996) 384-387
7. Rossert J., et al. Anti-erythropoietin antibodies and pure red-cell aplasia. J. Am. Soc. Nephrol. 15 (2004) 398-406
8. Casadevall N., et al. Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346 (2002) 469-475
9. Kutler D.J., and Begley C.G. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 100 (2002) 3457-3469
10. Bugelski P.J., and Treacy G. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr. Opin. Mol. Ther. 6 (2004) 10-16
11. Rosenberg A.S., and Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 3: effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies. Biopharm International 18 (2005) 32-36. http://www.biopharminternational.com/biopharm/article/articleDetail.jsp? id146216&pageID2 (==http://www.biopharminternational.com/biopharm/article/articleDetail.j sp?id=146216&pageID=2)
12. Proceedings of the international Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use (1997) Tripartite guideline S6 Preclinical Safety Evaluation Of Biotechnology-derived Pharmaceuticals (http://www.ich.org/LOB/media/MEDIA503.pdf)
13. Zwickl C.M., et al. Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys. Fundam. Appl. Toxicol. 16 (1991) 275-287
14. Wierda D., et al. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 158 (2001) 71-74
15. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 1 (2002) 457-462
16. Rosenberg A.S., and Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 1: considering consequences of the immune response to a protein. Biopharm International 17 (2004) 22-26. http://www.biopharminternational.com/biopharm/article/articleDetail.jsp? id134110&pageID134110&pageID2 (===http://www.biopharminternational.com/biopharm/article/articleDetail. jsp?id=134110&pageID=134110&pageID=2)
17. Rosenberg A.S., and Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 2: considering host-specific and product-specific factors impacting immunogenicity. Biopharm International 17 (2004) 34-42. http://www.biopharminternational.com/biopharm/article/articleDetail.jsp? id140695&sk&date&pageID4 (====http://www.biopharminternational.com/biopharm/article/articleDetail .jsp?id=140695&sk=&date=&pageID=4)
18. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (1998) The CDER Handbook (http://www.fda.gov/cder/handbook)
19. Center for Drug Evaluation and Research Center for Biologics Evaluation and Research (1995) Guidance for industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products (http://www.fda.gov/cder/guidance/clin2.pdf)
20. US Department of Health and Human Services Food and Drug Administration (2002) Draft Guidance for Industry and Reviewers on Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers (http://www.fda.gov/OHRMS/DOCKETS/98fr/03-906.htm)
21. US Department of Health and Human Services Food and Drug Administration (2004) Guidance for Industry Developing Medical Imaging Drugs and Biological Products. Part 1: Conducting Safety Assessments (http://www.fda.gov/cber/gdlns/medimagesaf.pdf)
22. US Department of Health and Human Services Food and Drug Administration (2002) Guidance for Industry Immunotoxicology Evaluation of Investigational New Drugs (http://www.fda.gov/cder/guidance/4945fnl.PDF)
23. US Department of Health and Human Services Food and Drug Administration (2000) Draft Guidance for Industry Chronic Cutaneous Ulcer and Burn Wounds - Developing Products for Treatments (http://www.fda.gov/cder/guidance/3226dft.pdf)
24. Center for Drug Evaluation and Research (2004) Manual of Policies and Procedures (MAPP) (http://www.fda.gov/cder/mapp.htm)
25. US Department of Health and Human Services Food and Drug Administration (1999) Guidance for Industry Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA) (http://www.fda.gov/cber/gdlns/rheumcln.pdf)
26. US Department of Health and Human Services Food and Drug Administration (2004) Guidance for Industry Premarketing Risk Assessment (http://www.fda.gov/cder/guidance/6357fnl.pdf)
27. The European Agency for the Evaluation of Medicinal Products (EMEA) (2003) The Common Technical Document for the Registration of Pharmaceuticals for Human Use. Efficacy - ICH M4E. Clinical Overview and Clinical Summary of Module 2. Module 5: Clinical Study Reports (http://www.tga.gov.au/docs/pdf/euguide/ich/ctdm2efficacy.pdf)
28. US Department of Health and Human Services Food and Drug Administration (1997) Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (http://www.fda.gov/cber/gdlns/ptc_mab.pdf)
29. US Department of Health and Human Services Food and Drug Administration (2002) Draft Guidance for Industry Drugs, Biologics, and Medical Devices Derived from Bioengineered Plants for Use in Humans and Animals (http://www.fda.gov/cber/gdlns/bioplant.pdf)
30. Center for Drug Evaluation and Research Center for Biologics Evaluation and Research (1994) Guidance for Industry for the Submission of Chemistry, Manufacturing, and Controls Information for Synthetic Peptide Substances (http://www.fda.gov/cber/gdlns/cmcsyn.pdf)
31. US Department of Health and Human Services Food and Drug Administration (1999) Draft Guidance for Industry for Platelet Testing and Evaluation of Platelet Substitute Products (http://www.fda.gov/cber/gdlns/platelet.pdf)
32. The European Agency for the Evaluation of Medicinal Products (EMEA) (2003) Guideline on Comparability of Medicinal Products Containing Biotechnology-derived Proteins as Active Substance: Non-clinical and Clinical Issues EMEA/CPMP/3097/02/Final (http://www.emea.eu.int/pdfs/human/ewp/309702en.pdf)
33. International conference on harmonization (ICH) of technical requirements for registration of pharmaceuticals for human use (2004) ICH Harmonized Tripartite Guideline Q5E Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process (CPMP/ICH/5721/03) (http://www.emea.eu.int/pdfs/human/ich/572103en.pdf)
34. Code of Federal Regulations 21 CFR Part 58: Good Laboratory Practice for Non-clinical Laboratory Studies, US Government Printing Office, Washington US (http://www.access.gpo.gov/nara/cfr/waisidx_00/21cfr58_00.html)
35. Organisation for Economic Co-operation and Development (1997) The OECD Principles on Good Laboratory Practice ENV/MC/CHEM (98)17 (http://www.olis.oecd.org/olis/1998doc.nsf/87fae4004d4fa67ac125685d00530 0b3/3d81d76159dd69e78025675c00409638?OpenDocument)
36. Mire-Sluis A.R., et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289 (2004) 1-16
37. Wadhwa M., et al. Strategies for detection, measurement, and characterization of unwanted antibodies induced by therapeutic biologicals. J. Immunol. Methods 278 (2003) 1-17
38. Geng D., et al. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J. Pharm. Biomed. Anal. 39 (2005) 364-375
39. US Department of Health and Human Services, Food and Drug Administration (CDER and CVM) (2001) Guidance For Industry Bioanalytical Method Validation (http://www.fda.gov/cder/guidance/4252fnl.pdf)
40. International conference on harminization (ICH) of technical requirements for registration of pharmaceuticals for human use (1995) ICH Harmonized Tripartite Guideline - Q2A, Text on validation of analytical procedures (http://www.fda.gov/cder/guidance/ichq2a.pdf)
41. International conference on harminization (ICH) of technical requirements for registration of pharmaceuticals for human use (1996) ICH Harmonized Tripartite Guideline - Q2B. Validation of analytical procedures: methodology (http://www.fda.gov/cder/guidance/1320fnl.pdf)